Apellis Pharmaceuticals Stock Filter Stocks by Fundamentals
| APLS Stock | USD 18.26 0.44 2.47% |
Fundamental analysis of Apellis Pharmaceuticals allows traders to better anticipate movements in Apellis Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Apellis | Shares Owned by Institutions | Build AI portfolio with Apellis Stock |
Apellis Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Apellis Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Apellis Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Apellis Pharmaceuticals' value.| Shares | Siren, L.l.c. | 2025-03-31 | 2.6 M | Jennison Associates Llc | 2025-03-31 | 2.5 M | Octagon Capital Advisors Lp | 2025-03-31 | 2.1 M | Geode Capital Management, Llc | 2025-03-31 | 2 M | Deutsche Bank Ag | 2025-03-31 | 1.8 M | Braidwell Lp | 2025-03-31 | 1.7 M | Suvretta Capital Management, Llc | 2025-03-31 | 1.6 M | Polar Capital Holdings Plc | 2025-03-31 | 1.6 M | Fmr Inc | 2025-03-31 | 1.5 M | Wellington Management Company Llp | 2025-03-31 | 12.3 M | Venbio Select Advisor Llc | 2025-03-31 | 12.2 M |
Apellis Fundamentals
| Return On Equity | -1.04 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.29) % | ||||
| Operating Margin | (0.50) % | ||||
| Current Valuation | 2.41 B | ||||
| Shares Outstanding | 125.68 M | ||||
| Shares Owned By Insiders | 13.77 % | ||||
| Shares Owned By Institutions | 86.23 % | ||||
| Number Of Shares Shorted | 25.14 M | ||||
| Price To Earning | (6.94) X | ||||
| Price To Book | 13.98 X | ||||
| Price To Sales | 2.96 X | ||||
| Revenue | 781.37 M | ||||
| Gross Profit | 314.68 M | ||||
| EBITDA | (154.53 M) | ||||
| Net Income | (197.88 M) | ||||
| Cash And Equivalents | 852.8 M | ||||
| Cash Per Share | 7.76 X | ||||
| Total Debt | 469.78 M | ||||
| Debt To Equity | 0.63 % | ||||
| Current Ratio | 7.57 X | ||||
| Book Value Per Share | 1.31 X | ||||
| Cash Flow From Operations | (87.87 M) | ||||
| Short Ratio | 10.34 X | ||||
| Earnings Per Share | (1.80) X | ||||
| Price To Earnings To Growth | (0.30) X | ||||
| Target Price | 35.35 | ||||
| Number Of Employees | 705 | ||||
| Beta | 0.67 | ||||
| Market Capitalization | 2.29 B | ||||
| Total Asset | 885.05 M | ||||
| Retained Earnings | (3.04 B) | ||||
| Working Capital | 603.45 M | ||||
| Current Asset | 115.82 M | ||||
| Current Liabilities | 5.13 M | ||||
| Net Asset | 885.05 M |
About Apellis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.